エクソソーム技術のグローバル市場（2023-2031年）：ロードカーゴ、ノンカーゴ

• 英文タイトル：Exosome Technologies Market (Exosome Type: Loaded Cargos [Peptide, siRNA, mRNA, miRNA, Protein, Chemical, and Others] and Non-cargo) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

• レポートコード：MRC2307A0201 • 出版社/出版日：Transparency Market Research / 2023年4月 • レポート形態：英文、PDF、208ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の市場調査資料によると、世界のエクソソーム技術市場規模は2023年の47.3百万ドルから2031年には343.5百万ドルへ上り、予想期間中、年平均24.8％拡大すると予測されています。本調査資料では、エクソソーム技術の世界市場を調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、エクソソーム種類別（ロードカーゴ、ノンカーゴ）分析、細胞源別（HEK293細胞、間葉系幹細胞、血小板、赤血球、その他）分析、用途別（治療薬、診断薬）分析、エンドユーザー別（医療提供者、製薬・バイオテクノロジー企業、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて明らかにしています。なお、本書に記載されている企業情報には、AEGLE Therapeutics、Aruna Bio, Inc.、Bio-Techne Corporation、Carmine Therapeutics, Inc.、Codiak BioSciences, Inc.、Creative Biolabs、Danaher Corporation (Beckman Coulter, Inc.)、Fujifilm Holdings Corporationなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要洞察 ・世界のエクソソーム技術市場規模：エクソソーム種類別 - ロードカーゴエクソソーム技術の市場規模 - ノンカーゴエクソソーム技術の市場規模 ・世界のエクソソーム技術市場規模：細胞源別 - HEK293細胞における市場規模 - 間葉系幹細胞における市場規模 - 血小板における市場規模 - 赤血球における市場規模 - その他細胞源における市場規模 ・世界のエクソソーム技術市場規模：用途別 - 治療薬における市場規模 - 診断薬における市場規模 ・世界のエクソソーム技術市場規模：エンドユーザー別 - 医療提供者における市場規模 - 製薬・バイオテクノロジー企業における市場規模 - その他エンドユーザーにおける市場規模 ・世界のエクソソーム技術市場規模：地域別 - 北米のエクソソーム技術市場規模 - ヨーロッパのエクソソーム技術市場規模 - アジア太平洋のエクソソーム技術市場規模 - 中南米のエクソソーム技術市場規模 - 中東・アフリカのエクソソーム技術市場規模 ・競争状況

Exosome Technologies Market – Scope of Report
TMR’s report on the global Exosome Technologies Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Exosome Technologies Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Exosome Technologies Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Exosome Technologies Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Exosome Technologies Market profiled in this report.

Key Questions Answered in Global Exosome Technologies Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Exosome Technologies Market – Research Objectives and Research Approach
The comprehensive report on the global Exosome Technologies Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Exosome Technologies Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
”

レポート目次

---

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Exosome Technologies Market
4. Market Overview
    4.1. Introduction
        4.1.1. Exosome Type Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Exosome Technologies Market Analysis and Forecasts, 2017 – 2031
        4.4.1. Market Revenue Projections (US$ Mn)
        4.4.2. Market Volume/Unit Shipments Projections
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Technological Advancements
    5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Exosome Technologies Market Analysis and Forecasts, by Exosome Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Exosome Type, 2017 – 2031
        6.3.1. Loaded Cargos
            6.3.1.1. Peptide
            6.3.1.2. siRNA
            6.3.1.3. mRNA
            6.3.1.4. miRNA
            6.3.1.5. Protein
            6.3.1.6. Chemical
            6.3.1.7. Others
        6.3.2. Non-cargo
    6.4. Market Attractiveness By Exosome Type
7. Global Exosome Technologies Market Analysis and Forecasts, by Cell Source
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Cell Source, 2017 – 2031
        7.3.1. HEK293 Cells
        7.3.2. MSCs
        7.3.3. Platelets
        7.3.4. Erythrocytes
        7.3.5. Natural Killer Cells
        7.3.6. Others
    7.4. Market Attractiveness By Cell Source
8. Global Exosome Technologies Market Analysis and Forecasts, by Application
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By Application, 2017 – 2031
        8.3.1. Therapeutics
            8.3.1.1. Oncology
            8.3.1.2. Neurodegenerative Diseases
            8.3.1.3. Cardiovascular Diseases
            8.3.1.4. Infectious Diseases
            8.3.1.5. Cosmetics
        8.3.2. Diagnostics
    8.4. Market Attractiveness By Application
9. Global Exosome Technologies Market Analysis and Forecasts, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast By End-user, 2017 – 2031
        9.3.1. Health Care Providers
        9.3.2. Pharmaceutical & Biotechnology Companies
        9.3.3. Others
    9.4. Market Attractiveness By End-user
10. Global Exosome Technologies Market Analysis and Forecasts, by Region
    10.1. Key Findings
    10.2. Market Value Forecast By Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Exosome Technologies Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Exosome Type, 2017 – 2031
        11.2.1. Loaded Cargos
            11.2.1.1. Peptide
            11.2.1.2. siRNA
            11.2.1.3. mRNA
            11.2.1.4. miRNA
            11.2.1.5. Protein
            11.2.1.6. Chemical
            11.2.1.7. Others
        11.2.2. Non-cargo
    11.3. Market Value Forecast By Cell Source, 2017 – 2031
        11.3.1. HEK293 Cells
        11.3.2. MSCs
        11.3.3. Platelets
        11.3.4. Erythrocytes
        11.3.5. Natural Killer Cells
        11.3.6. Others
    11.4. Market Value Forecast By Application, 2017 – 2031
        11.4.1. Therapeutics
            11.4.1.1. Oncology
            11.4.1.2. Neurodegenerative Diseases
            11.4.1.3. Cardiovascular Diseases
            11.4.1.4. Infectious Diseases
            11.4.1.5. Cosmetics
        11.4.2. Diagnostics
    11.5. Market Value Forecast By End-user, 2017 – 2031
        11.5.1. Health Care Providers
        11.5.2. Pharmaceutical & Biotechnology Companies
        11.5.3. Others
    11.6. Market Value Forecast By Country, 2017 – 2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Exosome Type
        11.7.2. By Cell Source
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Exosome Technologies Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Exosome Type, 2017 – 2031
        12.2.1. Loaded Cargos
            12.2.1.1. Peptide
            12.2.1.2. siRNA
            12.2.1.3. mRNA
            12.2.1.4. miRNA
            12.2.1.5. Protein
            12.2.1.6. Chemical
            12.2.1.7. Others
        12.2.2. Non-cargo
    12.3. Market Value Forecast By Cell Source, 2017 – 2031
        12.3.1. HEK293 Cells
        12.3.2. MSCs
        12.3.3. Platelets
        12.3.4. Erythrocytes
        12.3.5. Natural Killer Cells
        12.3.6. Others
    12.4. Market Value Forecast By Application, 2017 – 2031
        12.4.1. Therapeutics
            12.4.1.1. Oncology
            12.4.1.2. Neurodegenerative Diseases
            12.4.1.3. Cardiovascular Diseases
            12.4.1.4. Infectious Diseases
            12.4.1.5. Cosmetics
        12.4.2. Diagnostics
    12.5. Market Value Forecast By End-user, 2017 – 2031
        12.5.1. Health Care Providers
        12.5.2. Pharmaceutical & Biotechnology Companies
        12.5.3. Others
    12.6. Market Value Forecast By Country, 2017 – 2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Exosome Type
        12.7.2. By Cell Source
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country
13. Asia Pacific Exosome Technologies Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Exosome Type, 2017 – 2031
        13.2.1. Loaded Cargos
            13.2.1.1. Peptide
            13.2.1.2. siRNA
            13.2.1.3. mRNA
            13.2.1.4. miRNA
            13.2.1.5. Protein
            13.2.1.6. Chemical
            13.2.1.7. Others
        13.2.2. Non-cargo
    13.3. Market Value Forecast By Cell Source, 2017 – 2031
        13.3.1. HEK293 Cells
        13.3.2. MSCs
        13.3.3. Platelets
        13.3.4. Erythrocytes
        13.3.5. Natural Killer Cells
        13.3.6. Others
    13.4. Market Value Forecast By Application, 2017 – 2031
        13.4.1. Therapeutics
            13.4.1.1. Oncology
            13.4.1.2. Neurodegenerative Diseases
            13.4.1.3. Cardiovascular Diseases
            13.4.1.4. Infectious Diseases
            13.4.1.5. Cosmetics
        13.4.2. Diagnostics
    13.5. Market Value Forecast By End-user, 2017 – 2031
        13.5.1. Health Care Providers
        13.5.2. Pharmaceutical & Biotechnology Companies
        13.5.3. Others
    13.6. Market Value Forecast By Country, 2017 – 2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Exosome Type
        13.7.2. By Cell Source
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country
14. Latin America Exosome Technologies Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Exosome Type, 2017 – 2031
        14.2.1. Loaded Cargos
            14.2.1.1. Peptide
            14.2.1.2. siRNA
            14.2.1.3. mRNA
            14.2.1.4. miRNA
            14.2.1.5. Protein
            14.2.1.6. Chemical
            14.2.1.7. Others
        14.2.2. Non-cargo
    14.3. Market Value Forecast By Cell Source, 2017 – 2031
        14.3.1. HEK293 Cells
        14.3.2. MSCs
        14.3.3. Platelets
        14.3.4. Erythrocytes
        14.3.5. Natural Killer Cells
        14.3.6. Others
    14.4. Market Value Forecast By Application, 2017 – 2031
        14.4.1. Therapeutics
            14.4.1.1. Oncology
            14.4.1.2. Neurodegenerative Diseases
            14.4.1.3. Cardiovascular Diseases
            14.4.1.4. Infectious Diseases
            14.4.1.5. Cosmetics
        14.4.2. Diagnostics
    14.5. Market Value Forecast By End-user, 2017 – 2031
        14.5.1. Health Care Providers
        14.5.2. Pharmaceutical & Biotechnology Companies
        14.5.3. Others
    14.6. Market Value Forecast By Country, 2017 – 2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Exosome Type
        14.7.2. By Cell Source
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country
15. Middle East & Africa Exosome Technologies Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast By Exosome Type, 2017 – 2031
        15.2.1. Loaded Cargos
            15.2.1.1. Peptide
            15.2.1.2. siRNA
            15.2.1.3. mRNA
            15.2.1.4. miRNA
            15.2.1.5. Protein
            15.2.1.6. Chemical
            15.2.1.7. Others
        15.2.2. Non-cargo
    15.3. Market Value Forecast By Cell Source, 2017 – 2031
        15.3.1. HEK293 Cells
        15.3.2. MSCs
        15.3.3. Platelets
        15.3.4. Erythrocytes
        15.3.5. Natural Killer Cells
        15.3.6. Others
    15.4. Market Value Forecast By Application, 2017 – 2031
        15.4.1. Therapeutics
            15.4.1.1. Oncology
            15.4.1.2. Neurodegenerative Diseases
            15.4.1.3. Cardiovascular Diseases
            15.4.1.4. Infectious Diseases
            15.4.1.5. Cosmetics
        15.4.2. Diagnostics
    15.5. Market Value Forecast By End-user, 2017 – 2031
        15.5.1. Health Care Providers
        15.5.2. Pharmaceutical & Biotechnology Companies
        15.5.3. Others
    15.6. Market Value Forecast By Country, 2017 – 2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Exosome Type
        15.7.2. By Cell Source
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2021)
    16.3. Company Profiles
        16.3.1. AEGLE Therapeutics
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Test Type Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Aruna Bio, Inc.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Test Type Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Bio-Techne Corporation (Exosome Diagnostics, Inc.)
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Test Type Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Carmine Therapeutics, Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Test Type Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Codiak BioSciences, Inc.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Test Type Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Creative Biolabs
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Test Type Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Danaher Corporation (Beckman Coulter, Inc.)
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Test Type Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Fujifilm Holdings Corporation
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Test Type Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. NOVADIP Biosciences S.A.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Test Type Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. OmniSpirant Limited
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Test Type Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Thermo Fisher Scientific, Inc.
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Test Type Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview

List of Tables

Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 08: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 15: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 22: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 29: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 36: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

---